Left Menu
Development News Edition

EXCLUSIVE-AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week -sources

The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources. UK regulatory officials previously reviewed the illness and determined there was “insufficient evidence to say for certain” that it was or was not related to the vaccine.

Reuters | Updated: 20-10-2020 22:39 IST | Created: 20-10-2020 22:10 IST
EXCLUSIVE-AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week -sources
Representative image Image Credit: Wikimedia

AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness, four sources told Reuters.

AstraZeneca's large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company's UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis. The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said.

The FDA did not respond to a request for comment. The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources.

UK regulatory officials previously reviewed the illness and determined there was "insufficient evidence to say for certain" that it was or was not related to the vaccine. It permitted the trial to resume enrolling participants in the UK, according to a draft of the updated consent form shared with Reuters. "In this case, after considering the information, the independent reviewers and MHRA (Medicines and Healthcare products Regulatory Agency) recommended that vaccinations should continue," the draft consent form stated. "Close monitoring of the affected individual and other participants will be continued."

Regulators in Brazil, India and South Africa also previously allowed AstraZeneca to resume its vaccine trials there. Responding to a request, British regulators shared with Reuters a draft of a form letter to UK vaccine trial participants, dated Oct. 14 and signed by the Oxford COVID-19 Vaccine Team. It says the U.S. FDA had "completed their analysis" and said vaccination in the United States would resume shortly.

FDA "has come to the same conclusion as the other drug regulators including the MHRA," the letter states. The regulator, Health Research Authority, did not say if the letter had been sent or immediately respond to questions about it. An AstraZeneca spokeswoman said the communication is not from the company and it "cannot verify the content," referring to the draft letter to patients.

"We also cannot comment on a pending FDA decision," she said.


TRENDING

OPINION / BLOG / INTERVIEW

Turbulence surrounding tobacco control in Ghana

... ...

Smart healthcare: IoT redefining the way healthcare is delivered

As the world is embracing the new wave of digitalization triggered by the pandemic and the arrival of 5G, the adoption of IoT devices will further boom. With adoption set to soar, IoT security issues and other challenges cant be ignored any...

Refugee compassion and response: Ideas to mitigate disasters now and in their future

Their homeland becomes a forbidden territory for them and more likely than not, their journey to foreign soil is no less traumatizing, not to say deadly. It is crucial to help refugees live a life of dignity and purpose....

Inadequate water infrastructure causes a tidal wave of coronavirus in rural Alaska

... ...

Videos

Latest News

Most imported pesticides not made in India; hike in import duty to hit farmers: Dhanuka Agritech

Most of the imported pesticides like Cartap Hydrochloride are not manufactured in India and any move to increase customs duty on them will make these products costlier for domestic farmers, Dhanuka Agritech Chairman R G Agarwal said on Wedn...

UP export policy aims doubling farmer income, boosting agri-product shipments

The UP Export Policy 2020-25 approved by the state cabinet aims at doubling the income of farmers and increasing exports from the agricultural sector, the state government said on Wednesday. The policy, which was given a green signal by Chi...

Roshni Act: Farooq's sister, mahant, prominent hoteliers in second list issued by JK admin

National Conference president Farooq Abdullahs sister, an influential mahant and two prominent hoteliers including a Congress leader figure in the second list of 269 people who have availed land under the now-scrapped Roshni Act. The Jammu ...

Feuding no more, Pelé joins world in mourning Diego Maradona

The most heated wrangling over the title of soccers greatest player could be found between Diego Maradona and Pel themselves. So often, their squabbling would descend into acrimonious barbs and taunts launched between the finest to play the...

Give Feedback